Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 756-757

  Watt, Tanya C ^a   Cooper, Todd ^a  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

AML; Pediatrics; Relapse; Sorafenib

Indexed keywords

ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB; HYDROCORTISONE; METHOTREXATE; MITOXANTRONE; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; FASCIITIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROTEIN KINASE INHIBITORS; PYRIDINES; RECURRENCE; REMISSION INDUCTION;

EID: 84864928986     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23394     Document Type: Article

References (15)

1. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemia: An update. J Clin Oncol 2011; 29: 551-565.
2. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Structural and numerical variation of flt3/itd in pediatric aml. Blood 2008; 111: 4930-4933.
3. Ravandi F, Cortes JE, Jones D, et al. Phase i/ii study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 1856-1862.
4. Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in treatment of acute myeloid leukemia. Leuk Lymphoma 2008; 49: 2246-2255.
5. Brown P, Meshinchi S, Levis M, et al. Pediatric aml primary samples with flt3/itd mutations are preferentially killed by flt3 inhibition. Blood 2004; 104: 1841-1849.
6. Lowinger TB, Riedl B, Dumas J, et al. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002; 8: 2269-2278.
7. Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ash annual meeting highlights. J Hematol Oncol 2010; 3: 17.
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 2008; 359: 378-390.
9. Widemann BC, Fox E, Adamson PC, et al. Phase I study of sorafenib in children with refractory solid tumors: A children's oncology group phase I consortium trial. J Clin Oncol (Meeting Abstracts) 2009; 27: 10012.
10. Zhang W, Konopleva M, Shi YX, et al. Mutant flt3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008 100: 184-198.
11. Safaian NN, Czibere A, Bruns I, et al. Sorafenib (nexavar) induces molecular remission and regression of extramedullary disease in a patient with flt3-itd+ acute myeloid leukemia. Leuk Res 2009; 33: 348-350.
12. Winkler J, Rech D, Kallert S, et al. Sorafenib induces sustained molecular remission in flt3-itd positive aml with relapse after second allogeneic stem cell transplantation without exacerbation of acute gvhd: A case report. Leuk Res 2010; 34: 270-272.
13. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in flt3-itd-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567-6571.
14. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011; 29: 3293-3300.
15. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12: 426-437.